Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cx717
1. Cx717
2. 867276-98-0
3. Cx-717
4. Unii-7i12yta3qm
5. 7i12yta3qm
6. Benzo[c][1,2,5]oxadiazol-5-yl(morpholino)methanone
7. 2,1,3-benzoxadiazol-5-yl-4-morpholinylmethanone
8. Cx 717
9. Morpholine, 4-(2,1,3-benzoxadiazol-5-ylcarbonyl)-
10. 211735-82-9
11. Starbld0003244
12. Cx 717 (pharmaceutical)
13. Oprea1_513346
14. Schembl243542
15. Chembl4791762
16. Dtxsid301241632
17. Ex-a6414
18. Db05047
19. Bs-47001
20. Cs-0256234
| Molecular Weight | 233.22 g/mol |
|---|---|
| Molecular Formula | C11H11N3O3 |
| XLogP3 | 0.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 1 |
| Exact Mass | 233.08004122 g/mol |
| Monoisotopic Mass | 233.08004122 g/mol |
| Topological Polar Surface Area | 68.5 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 294 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
CX-717 is an ampakine compound. It is a positive allosteric modulator of AMPA receptors. Its action is theorized to be due to the facilitation of transmission at cortical synapses that use glutamate as a neurotransmitter. This in turn may promote plasticity at the synapse, which could translate into better cognitive performance. CX-717 works by allosterically binding to particular receptors in the brain, called AMPA-type glutamate receptors. This boosts the activity of glutamate, a neurotransmitter, and makes it easier to encode memory and to learn. In addition, CX717 could potentially strongly impact the up-regulation of BDNF (brain-derived neurotrophic factor) or NGF (nerve growth factor), two growth factors known to stimulate the formation of new circuitry in the brain associated with forming memory and cognition.
ABOUT THIS PAGE
64
PharmaCompass offers a list of CX717 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right CX717 manufacturer or CX717 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CX717 manufacturer or CX717 supplier.
PharmaCompass also assists you with knowing the CX717 API Price utilized in the formulation of products. CX717 API Price is not always fixed or binding as the CX717 Price is obtained through a variety of data sources. The CX717 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CX717 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CX717, including repackagers and relabelers. The FDA regulates CX717 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CX717 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CX717 supplier is an individual or a company that provides CX717 active pharmaceutical ingredient (API) or CX717 finished formulations upon request. The CX717 suppliers may include CX717 API manufacturers, exporters, distributors and traders.
CX717 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CX717 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CX717 GMP manufacturer or CX717 GMP API supplier for your needs.
A CX717 CoA (Certificate of Analysis) is a formal document that attests to CX717's compliance with CX717 specifications and serves as a tool for batch-level quality control.
CX717 CoA mostly includes findings from lab analyses of a specific batch. For each CX717 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CX717 may be tested according to a variety of international standards, such as European Pharmacopoeia (CX717 EP), CX717 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CX717 USP).
